

# Global Oligonucleotide Therapy-based Drug Market Research Report 2024, Forecast to 2032

<https://marketpublishers.com/r/GD652840ADA6EN.html>

Date: October 2024

Pages: 159

Price: US\$ 3,400.00 (Single User License)

ID: GD652840ADA6EN

## Abstracts

### Report Overview

Oligonucleotides can be used to modulate gene expression via a range of processes including RNAi, target degradation by RNase H-mediated cleavage, splicing modulation, non-coding RNA inhibition, gene activation and programmed gene editing.

The global Oligonucleotide Therapy-based Drug market size was estimated at USD 63950 million in 2023 and is projected to reach USD 88684.83 million by 2032, exhibiting a CAGR of 3.70% during the forecast period.

North America Oligonucleotide Therapy-based Drug market size was estimated at USD 17737.25 million in 2023, at a CAGR of 3.17% during the forecast period of 2024 through 2032.

This report provides a deep insight into the global Oligonucleotide Therapy-based Drug market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.

The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Oligonucleotide Therapy-based Drug Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the

main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.

In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Oligonucleotide Therapy-based Drug market in any manner.

### Global Oligonucleotide Therapy-based Drug Market: Market Segmentation Analysis

The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.

#### Key Company

Sarepta Therapeutics

Ionis Pharmaceuticals

Alnylam

Biogen

Nippon Shinyaku

Sobi

Novartis

BioNTech

Pfizer

Moderna Therapeutics

Jazz Pharmaceuticals

CureVac

Regulus Therapeutics

ProQR

Secarna

MiNA Therapeutics

Sylentis

Arrowhead

Silence Therapeutics

Dicerna

Market Segmentation (by Type)

Antisense Oligonucleotides (ASO)

siRNA

mRNA

Market Segmentation (by Application)

Neuromuscular Diseases

hATTR

COVID-19

Other

Geographic Segmentation

North America (USA, Canada, Mexico)

Europe (Germany, UK, France, Russia, Italy, Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)

South America (Brazil, Argentina, Columbia, Rest of South America)

The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

#### Key Benefits of This Market Research:

Industry drivers, restraints, and opportunities covered in the study

Neutral perspective on the market performance

Recent industry trends and developments

Competitive landscape & strategies of key players

Potential & niche segments and regions exhibiting promising growth covered

Historical, current, and projected market size, in terms of value

In-depth analysis of the Oligonucleotide Therapy-based Drug Market

Overview of the regional outlook of the Oligonucleotide Therapy-based Drug Market:

#### Key Reasons to Buy this Report:

Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change

This enables you to anticipate market changes to remain ahead of your competitors

You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents

The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly

Provision of market value data for each segment and sub-segment

Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market

Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region

Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled

Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players

The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions

Includes in-depth analysis of the market from various perspectives through Porter's five forces analysis

Provides insight into the market through Value Chain

Market dynamics scenario, along with growth opportunities of the market in the years to come

6-month post-sales analyst support

## Customization of the Report

In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.

## Chapter Outline

Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Oligonucleotide Therapy-based Drug Market and its likely evolution in the short to mid-term, and long term.

Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region from the consumer side and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 shares the main producing countries of Oligonucleotide Therapy-based Drug, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.

Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 11 provides a quantitative analysis of the market size and development potential of each region during the forecast period.

Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment during the forecast period.

Chapter 13 is the main points and conclusions of the report.

## Contents

### **1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE**

- 1.1 Market Definition and Statistical Scope of Oligonucleotide Therapy-based Drug
- 1.2 Key Market Segments
  - 1.2.1 Oligonucleotide Therapy-based Drug Segment by Type
  - 1.2.2 Oligonucleotide Therapy-based Drug Segment by Application
- 1.3 Methodology & Sources of Information
  - 1.3.1 Research Methodology
  - 1.3.2 Research Process
  - 1.3.3 Market Breakdown and Data Triangulation
  - 1.3.4 Base Year
  - 1.3.5 Report Assumptions & Caveats

### **2 OLIGONUCLEOTIDE THERAPY-BASED DRUG MARKET OVERVIEW**

- 2.1 Global Market Overview
  - 2.1.1 Global Oligonucleotide Therapy-based Drug Market Size (M USD) Estimates and Forecasts (2019-2032)
  - 2.1.2 Global Oligonucleotide Therapy-based Drug Sales Estimates and Forecasts (2019-2032)
- 2.2 Market Segment Executive Summary
- 2.3 Global Market Size by Region

### **3 OLIGONUCLEOTIDE THERAPY-BASED DRUG MARKET COMPETITIVE LANDSCAPE**

- 3.1 Global Oligonucleotide Therapy-based Drug Sales by Manufacturers (2019-2024)
- 3.2 Global Oligonucleotide Therapy-based Drug Revenue Market Share by Manufacturers (2019-2024)
- 3.3 Oligonucleotide Therapy-based Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
- 3.4 Global Oligonucleotide Therapy-based Drug Average Price by Manufacturers (2019-2024)
- 3.5 Manufacturers Oligonucleotide Therapy-based Drug Sales Sites, Area Served, Product Type
- 3.6 Oligonucleotide Therapy-based Drug Market Competitive Situation and Trends
  - 3.6.1 Oligonucleotide Therapy-based Drug Market Concentration Rate

3.6.2 Global 5 and 10 Largest Oligonucleotide Therapy-based Drug Players Market Share by Revenue

3.6.3 Mergers & Acquisitions, Expansion

## **4 OLIGONUCLEOTIDE THERAPY-BASED DRUG INDUSTRY CHAIN ANALYSIS**

4.1 Oligonucleotide Therapy-based Drug Industry Chain Analysis

4.2 Market Overview of Key Raw Materials

4.3 Midstream Market Analysis

4.4 Downstream Customer Analysis

## **5 THE DEVELOPMENT AND DYNAMICS OF OLIGONUCLEOTIDE THERAPY-BASED DRUG MARKET**

5.1 Key Development Trends

5.2 Driving Factors

5.3 Market Challenges

5.4 Market Restraints

5.5 Industry News

5.5.1 New Product Developments

5.5.2 Mergers & Acquisitions

5.5.3 Expansions

5.5.4 Collaboration/Supply Contracts

5.6 Industry Policies

## **6 OLIGONUCLEOTIDE THERAPY-BASED DRUG MARKET SEGMENTATION BY TYPE**

6.1 Evaluation Matrix of Segment Market Development Potential (Type)

6.2 Global Oligonucleotide Therapy-based Drug Sales Market Share by Type (2019-2024)

6.3 Global Oligonucleotide Therapy-based Drug Market Size Market Share by Type (2019-2024)

6.4 Global Oligonucleotide Therapy-based Drug Price by Type (2019-2024)

## **7 OLIGONUCLEOTIDE THERAPY-BASED DRUG MARKET SEGMENTATION BY APPLICATION**

7.1 Evaluation Matrix of Segment Market Development Potential (Application)

7.2 Global Oligonucleotide Therapy-based Drug Market Sales by Application  
(2019-2024)

7.3 Global Oligonucleotide Therapy-based Drug Market Size (M USD) by Application  
(2019-2024)

7.4 Global Oligonucleotide Therapy-based Drug Sales Growth Rate by Application  
(2019-2024)

## **8 OLIGONUCLEOTIDE THERAPY-BASED DRUG MARKET CONSUMPTION BY REGION**

8.1 Global Oligonucleotide Therapy-based Drug Sales by Region

8.1.1 Global Oligonucleotide Therapy-based Drug Sales by Region

8.1.2 Global Oligonucleotide Therapy-based Drug Sales Market Share by Region

8.2 North America

8.2.1 North America Oligonucleotide Therapy-based Drug Sales by Country

8.2.2 U.S.

8.2.3 Canada

8.2.4 Mexico

8.3 Europe

8.3.1 Europe Oligonucleotide Therapy-based Drug Sales by Country

8.3.2 Germany

8.3.3 France

8.3.4 U.K.

8.3.5 Italy

8.3.6 Russia

8.4 Asia Pacific

8.4.1 Asia Pacific Oligonucleotide Therapy-based Drug Sales by Region

8.4.2 China

8.4.3 Japan

8.4.4 South Korea

8.4.5 India

8.4.6 Southeast Asia

8.5 South America

8.5.1 South America Oligonucleotide Therapy-based Drug Sales by Country

8.5.2 Brazil

8.5.3 Argentina

8.5.4 Columbia

8.6 Middle East and Africa

8.6.1 Middle East and Africa Oligonucleotide Therapy-based Drug Sales by Region

8.6.2 Saudi Arabia

8.6.3 UAE

8.6.4 Egypt

8.6.5 Nigeria

8.6.6 South Africa

## **9 OLIGONUCLEOTIDE THERAPY-BASED DRUG MARKET PRODUCTION BY REGION**

9.1 Global Production of Oligonucleotide Therapy-based Drug by Region (2019-2024)

9.2 Global Oligonucleotide Therapy-based Drug Revenue Market Share by Region (2019-2024)

9.3 Global Oligonucleotide Therapy-based Drug Production, Revenue, Price and Gross Margin (2019-2024)

9.4 North America Oligonucleotide Therapy-based Drug Production

9.4.1 North America Oligonucleotide Therapy-based Drug Production Growth Rate (2019-2024)

9.4.2 North America Oligonucleotide Therapy-based Drug Production, Revenue, Price and Gross Margin (2019-2024)

9.5 Europe Oligonucleotide Therapy-based Drug Production

9.5.1 Europe Oligonucleotide Therapy-based Drug Production Growth Rate (2019-2024)

9.5.2 Europe Oligonucleotide Therapy-based Drug Production, Revenue, Price and Gross Margin (2019-2024)

9.6 Japan Oligonucleotide Therapy-based Drug Production (2019-2024)

9.6.1 Japan Oligonucleotide Therapy-based Drug Production Growth Rate (2019-2024)

9.6.2 Japan Oligonucleotide Therapy-based Drug Production, Revenue, Price and Gross Margin (2019-2024)

9.7 China Oligonucleotide Therapy-based Drug Production (2019-2024)

9.7.1 China Oligonucleotide Therapy-based Drug Production Growth Rate (2019-2024)

9.7.2 China Oligonucleotide Therapy-based Drug Production, Revenue, Price and Gross Margin (2019-2024)

## **10 KEY COMPANIES PROFILE**

10.1 Sarepta Therapeutics

10.1.1 Sarepta Therapeutics Oligonucleotide Therapy-based Drug Basic Information

10.1.2 Sarepta Therapeutics Oligonucleotide Therapy-based Drug Product Overview

### 10.1.3 Sarepta Therapeutics Oligonucleotide Therapy-based Drug Product Market Performance

10.1.4 Sarepta Therapeutics Business Overview

10.1.5 Sarepta Therapeutics Oligonucleotide Therapy-based Drug SWOT Analysis

10.1.6 Sarepta Therapeutics Recent Developments

### 10.2 Ionis Pharmaceuticals

10.2.1 Ionis Pharmaceuticals Oligonucleotide Therapy-based Drug Basic Information

10.2.2 Ionis Pharmaceuticals Oligonucleotide Therapy-based Drug Product Overview

### 10.2.3 Ionis Pharmaceuticals Oligonucleotide Therapy-based Drug Product Market Performance

10.2.4 Ionis Pharmaceuticals Business Overview

10.2.5 Ionis Pharmaceuticals Oligonucleotide Therapy-based Drug SWOT Analysis

10.2.6 Ionis Pharmaceuticals Recent Developments

### 10.3 Alnylam

10.3.1 Alnylam Oligonucleotide Therapy-based Drug Basic Information

10.3.2 Alnylam Oligonucleotide Therapy-based Drug Product Overview

10.3.3 Alnylam Oligonucleotide Therapy-based Drug Product Market Performance

10.3.4 Alnylam Oligonucleotide Therapy-based Drug SWOT Analysis

10.3.5 Alnylam Business Overview

10.3.6 Alnylam Recent Developments

### 10.4 Biogen

10.4.1 Biogen Oligonucleotide Therapy-based Drug Basic Information

10.4.2 Biogen Oligonucleotide Therapy-based Drug Product Overview

10.4.3 Biogen Oligonucleotide Therapy-based Drug Product Market Performance

10.4.4 Biogen Business Overview

10.4.5 Biogen Recent Developments

### 10.5 Nippon Shinyaku

10.5.1 Nippon Shinyaku Oligonucleotide Therapy-based Drug Basic Information

10.5.2 Nippon Shinyaku Oligonucleotide Therapy-based Drug Product Overview

### 10.5.3 Nippon Shinyaku Oligonucleotide Therapy-based Drug Product Market Performance

10.5.4 Nippon Shinyaku Business Overview

10.5.5 Nippon Shinyaku Recent Developments

### 10.6 Sobi

10.6.1 Sobi Oligonucleotide Therapy-based Drug Basic Information

10.6.2 Sobi Oligonucleotide Therapy-based Drug Product Overview

10.6.3 Sobi Oligonucleotide Therapy-based Drug Product Market Performance

10.6.4 Sobi Business Overview

10.6.5 Sobi Recent Developments

## 10.7 Novartis

- 10.7.1 Novartis Oligonucleotide Therapy-based Drug Basic Information
- 10.7.2 Novartis Oligonucleotide Therapy-based Drug Product Overview
- 10.7.3 Novartis Oligonucleotide Therapy-based Drug Product Market Performance
- 10.7.4 Novartis Business Overview
- 10.7.5 Novartis Recent Developments

## 10.8 BioNTech

- 10.8.1 BioNTech Oligonucleotide Therapy-based Drug Basic Information
- 10.8.2 BioNTech Oligonucleotide Therapy-based Drug Product Overview
- 10.8.3 BioNTech Oligonucleotide Therapy-based Drug Product Market Performance
- 10.8.4 BioNTech Business Overview
- 10.8.5 BioNTech Recent Developments

## 10.9 Pfizer

- 10.9.1 Pfizer Oligonucleotide Therapy-based Drug Basic Information
- 10.9.2 Pfizer Oligonucleotide Therapy-based Drug Product Overview
- 10.9.3 Pfizer Oligonucleotide Therapy-based Drug Product Market Performance
- 10.9.4 Pfizer Business Overview
- 10.9.5 Pfizer Recent Developments

## 10.10 Moderna Therapeutics

- 10.10.1 Moderna Therapeutics Oligonucleotide Therapy-based Drug Basic Information
- 10.10.2 Moderna Therapeutics Oligonucleotide Therapy-based Drug Product Overview
- 10.10.3 Moderna Therapeutics Oligonucleotide Therapy-based Drug Product Market Performance
- 10.10.4 Moderna Therapeutics Business Overview
- 10.10.5 Moderna Therapeutics Recent Developments

## 10.11 Jazz Pharmaceuticals

- 10.11.1 Jazz Pharmaceuticals Oligonucleotide Therapy-based Drug Basic Information
- 10.11.2 Jazz Pharmaceuticals Oligonucleotide Therapy-based Drug Product Overview
- 10.11.3 Jazz Pharmaceuticals Oligonucleotide Therapy-based Drug Product Market Performance
- 10.11.4 Jazz Pharmaceuticals Business Overview
- 10.11.5 Jazz Pharmaceuticals Recent Developments

## 10.12 CureVac

- 10.12.1 CureVac Oligonucleotide Therapy-based Drug Basic Information
- 10.12.2 CureVac Oligonucleotide Therapy-based Drug Product Overview
- 10.12.3 CureVac Oligonucleotide Therapy-based Drug Product Market Performance
- 10.12.4 CureVac Business Overview
- 10.12.5 CureVac Recent Developments

## 10.13 Regulus Therapeutics

- 10.13.1 Regulus Therapeutics Oligonucleotide Therapy-based Drug Basic Information
- 10.13.2 Regulus Therapeutics Oligonucleotide Therapy-based Drug Product Overview
- 10.13.3 Regulus Therapeutics Oligonucleotide Therapy-based Drug Product Market Performance
- 10.13.4 Regulus Therapeutics Business Overview
- 10.13.5 Regulus Therapeutics Recent Developments
- 10.14 ProQR
  - 10.14.1 ProQR Oligonucleotide Therapy-based Drug Basic Information
  - 10.14.2 ProQR Oligonucleotide Therapy-based Drug Product Overview
  - 10.14.3 ProQR Oligonucleotide Therapy-based Drug Product Market Performance
  - 10.14.4 ProQR Business Overview
  - 10.14.5 ProQR Recent Developments
- 10.15 Secarna
  - 10.15.1 Secarna Oligonucleotide Therapy-based Drug Basic Information
  - 10.15.2 Secarna Oligonucleotide Therapy-based Drug Product Overview
  - 10.15.3 Secarna Oligonucleotide Therapy-based Drug Product Market Performance
  - 10.15.4 Secarna Business Overview
  - 10.15.5 Secarna Recent Developments
- 10.16 MiNA Therapeutics
  - 10.16.1 MiNA Therapeutics Oligonucleotide Therapy-based Drug Basic Information
  - 10.16.2 MiNA Therapeutics Oligonucleotide Therapy-based Drug Product Overview
  - 10.16.3 MiNA Therapeutics Oligonucleotide Therapy-based Drug Product Market Performance
  - 10.16.4 MiNA Therapeutics Business Overview
  - 10.16.5 MiNA Therapeutics Recent Developments
- 10.17 Sylentis
  - 10.17.1 Sylentis Oligonucleotide Therapy-based Drug Basic Information
  - 10.17.2 Sylentis Oligonucleotide Therapy-based Drug Product Overview
  - 10.17.3 Sylentis Oligonucleotide Therapy-based Drug Product Market Performance
  - 10.17.4 Sylentis Business Overview
  - 10.17.5 Sylentis Recent Developments
- 10.18 Arrowhead
  - 10.18.1 Arrowhead Oligonucleotide Therapy-based Drug Basic Information
  - 10.18.2 Arrowhead Oligonucleotide Therapy-based Drug Product Overview
  - 10.18.3 Arrowhead Oligonucleotide Therapy-based Drug Product Market Performance
  - 10.18.4 Arrowhead Business Overview
  - 10.18.5 Arrowhead Recent Developments
- 10.19 Silence Therapeutics
  - 10.19.1 Silence Therapeutics Oligonucleotide Therapy-based Drug Basic Information

- 10.19.2 Silence Therapeutics Oligonucleotide Therapy-based Drug Product Overview
- 10.19.3 Silence Therapeutics Oligonucleotide Therapy-based Drug Product Market Performance
- 10.19.4 Silence Therapeutics Business Overview
- 10.19.5 Silence Therapeutics Recent Developments
- 10.20 Dicerna
  - 10.20.1 Dicerna Oligonucleotide Therapy-based Drug Basic Information
  - 10.20.2 Dicerna Oligonucleotide Therapy-based Drug Product Overview
  - 10.20.3 Dicerna Oligonucleotide Therapy-based Drug Product Market Performance
  - 10.20.4 Dicerna Business Overview
  - 10.20.5 Dicerna Recent Developments

## **11 OLIGONUCLEOTIDE THERAPY-BASED DRUG MARKET FORECAST BY REGION**

- 11.1 Global Oligonucleotide Therapy-based Drug Market Size Forecast
- 11.2 Global Oligonucleotide Therapy-based Drug Market Forecast by Region
  - 11.2.1 North America Market Size Forecast by Country
  - 11.2.2 Europe Oligonucleotide Therapy-based Drug Market Size Forecast by Country
  - 11.2.3 Asia Pacific Oligonucleotide Therapy-based Drug Market Size Forecast by Region
  - 11.2.4 South America Oligonucleotide Therapy-based Drug Market Size Forecast by Country
  - 11.2.5 Middle East and Africa Forecasted Consumption of Oligonucleotide Therapy-based Drug by Country

## **12 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2032)**

- 12.1 Global Oligonucleotide Therapy-based Drug Market Forecast by Type (2025-2032)
  - 12.1.1 Global Forecasted Sales of Oligonucleotide Therapy-based Drug by Type (2025-2032)
  - 12.1.2 Global Oligonucleotide Therapy-based Drug Market Size Forecast by Type (2025-2032)
  - 12.1.3 Global Forecasted Price of Oligonucleotide Therapy-based Drug by Type (2025-2032)
- 12.2 Global Oligonucleotide Therapy-based Drug Market Forecast by Application (2025-2032)
  - 12.2.1 Global Oligonucleotide Therapy-based Drug Sales (K MT) Forecast by Application

12.2.2 Global Oligonucleotide Therapy-based Drug Market Size (M USD) Forecast by Application (2025-2032)

## **13 CONCLUSION AND KEY FINDINGS**

## List Of Tables

### LIST OF TABLES

Table 1. Introduction of the Type

Table 2. Introduction of the Application

Table 3. Market Size (M USD) Segment Executive Summary

Table 4. Oligonucleotide Therapy-based Drug Market Size Comparison by Region (M USD)

Table 5. Global Oligonucleotide Therapy-based Drug Sales (K MT) by Manufacturers (2019-2024)

Table 6. Global Oligonucleotide Therapy-based Drug Sales Market Share by Manufacturers (2019-2024)

Table 7. Global Oligonucleotide Therapy-based Drug Revenue (M USD) by Manufacturers (2019-2024)

Table 8. Global Oligonucleotide Therapy-based Drug Revenue Share by Manufacturers (2019-2024)

Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oligonucleotide Therapy-based Drug as of 2022)

Table 10. Global Market Oligonucleotide Therapy-based Drug Average Price (USD/MT) of Key Manufacturers (2019-2024)

Table 11. Manufacturers Oligonucleotide Therapy-based Drug Sales Sites and Area Served

Table 12. Manufacturers Oligonucleotide Therapy-based Drug Product Type

Table 13. Global Oligonucleotide Therapy-based Drug Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Mergers & Acquisitions, Expansion Plans

Table 15. Industry Chain Map of Oligonucleotide Therapy-based Drug

Table 16. Market Overview of Key Raw Materials

Table 17. Midstream Market Analysis

Table 18. Downstream Customer Analysis

Table 19. Key Development Trends

Table 20. Driving Factors

Table 21. Oligonucleotide Therapy-based Drug Market Challenges

Table 22. Global Oligonucleotide Therapy-based Drug Sales by Type (K MT)

Table 23. Global Oligonucleotide Therapy-based Drug Market Size by Type (M USD)

Table 24. Global Oligonucleotide Therapy-based Drug Sales (K MT) by Type (2019-2024)

Table 25. Global Oligonucleotide Therapy-based Drug Sales Market Share by Type

(2019-2024)

Table 26. Global Oligonucleotide Therapy-based Drug Market Size (M USD) by Type (2019-2024)

Table 27. Global Oligonucleotide Therapy-based Drug Market Size Share by Type (2019-2024)

Table 28. Global Oligonucleotide Therapy-based Drug Price (USD/MT) by Type (2019-2024)

Table 29. Global Oligonucleotide Therapy-based Drug Sales (K MT) by Application

Table 30. Global Oligonucleotide Therapy-based Drug Market Size by Application

Table 31. Global Oligonucleotide Therapy-based Drug Sales by Application (2019-2024) & (K MT)

Table 32. Global Oligonucleotide Therapy-based Drug Sales Market Share by Application (2019-2024)

Table 33. Global Oligonucleotide Therapy-based Drug Sales by Application (2019-2024) & (M USD)

Table 34. Global Oligonucleotide Therapy-based Drug Market Share by Application (2019-2024)

Table 35. Global Oligonucleotide Therapy-based Drug Sales Growth Rate by Application (2019-2024)

Table 36. Global Oligonucleotide Therapy-based Drug Sales by Region (2019-2024) & (K MT)

Table 37. Global Oligonucleotide Therapy-based Drug Sales Market Share by Region (2019-2024)

Table 38. North America Oligonucleotide Therapy-based Drug Sales by Country (2019-2024) & (K MT)

Table 39. Europe Oligonucleotide Therapy-based Drug Sales by Country (2019-2024) & (K MT)

Table 40. Asia Pacific Oligonucleotide Therapy-based Drug Sales by Region (2019-2024) & (K MT)

Table 41. South America Oligonucleotide Therapy-based Drug Sales by Country (2019-2024) & (K MT)

Table 42. Middle East and Africa Oligonucleotide Therapy-based Drug Sales by Region (2019-2024) & (K MT)

Table 43. Global Oligonucleotide Therapy-based Drug Production (K MT) by Region (2019-2024)

Table 44. Global Oligonucleotide Therapy-based Drug Revenue (US\$ Million) by Region (2019-2024)

Table 45. Global Oligonucleotide Therapy-based Drug Revenue Market Share by Region (2019-2024)

Table 46. Global Oligonucleotide Therapy-based Drug Production (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 47. North America Oligonucleotide Therapy-based Drug Production (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 48. Europe Oligonucleotide Therapy-based Drug Production (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 49. Japan Oligonucleotide Therapy-based Drug Production (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 50. China Oligonucleotide Therapy-based Drug Production (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 51. Sarepta Therapeutics Oligonucleotide Therapy-based Drug Basic Information

Table 52. Sarepta Therapeutics Oligonucleotide Therapy-based Drug Product Overview

Table 53. Sarepta Therapeutics Oligonucleotide Therapy-based Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 54. Sarepta Therapeutics Business Overview

Table 55. Sarepta Therapeutics Oligonucleotide Therapy-based Drug SWOT Analysis

Table 56. Sarepta Therapeutics Recent Developments

Table 57. Ionis Pharmaceuticals Oligonucleotide Therapy-based Drug Basic Information

Table 58. Ionis Pharmaceuticals Oligonucleotide Therapy-based Drug Product Overview

Table 59. Ionis Pharmaceuticals Oligonucleotide Therapy-based Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 60. Ionis Pharmaceuticals Business Overview

Table 61. Ionis Pharmaceuticals Oligonucleotide Therapy-based Drug SWOT Analysis

Table 62. Ionis Pharmaceuticals Recent Developments

Table 63. Alnylam Oligonucleotide Therapy-based Drug Basic Information

Table 64. Alnylam Oligonucleotide Therapy-based Drug Product Overview

Table 65. Alnylam Oligonucleotide Therapy-based Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 66. Alnylam Oligonucleotide Therapy-based Drug SWOT Analysis

Table 67. Alnylam Business Overview

Table 68. Alnylam Recent Developments

Table 69. Biogen Oligonucleotide Therapy-based Drug Basic Information

Table 70. Biogen Oligonucleotide Therapy-based Drug Product Overview

Table 71. Biogen Oligonucleotide Therapy-based Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 72. Biogen Business Overview

Table 73. Biogen Recent Developments

Table 74. Nippon Shinyaku Oligonucleotide Therapy-based Drug Basic Information

Table 75. Nippon Shinyaku Oligonucleotide Therapy-based Drug Product Overview

Table 76. Nippon Shinyaku Oligonucleotide Therapy-based Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 77. Nippon Shinyaku Business Overview

Table 78. Nippon Shinyaku Recent Developments

Table 79. Sobi Oligonucleotide Therapy-based Drug Basic Information

Table 80. Sobi Oligonucleotide Therapy-based Drug Product Overview

Table 81. Sobi Oligonucleotide Therapy-based Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 82. Sobi Business Overview

Table 83. Sobi Recent Developments

Table 84. Novartis Oligonucleotide Therapy-based Drug Basic Information

Table 85. Novartis Oligonucleotide Therapy-based Drug Product Overview

Table 86. Novartis Oligonucleotide Therapy-based Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 87. Novartis Business Overview

Table 88. Novartis Recent Developments

Table 89. BioNTech Oligonucleotide Therapy-based Drug Basic Information

Table 90. BioNTech Oligonucleotide Therapy-based Drug Product Overview

Table 91. BioNTech Oligonucleotide Therapy-based Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 92. BioNTech Business Overview

Table 93. BioNTech Recent Developments

Table 94. Pfizer Oligonucleotide Therapy-based Drug Basic Information

Table 95. Pfizer Oligonucleotide Therapy-based Drug Product Overview

Table 96. Pfizer Oligonucleotide Therapy-based Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 97. Pfizer Business Overview

Table 98. Pfizer Recent Developments

Table 99. Moderna Therapeutics Oligonucleotide Therapy-based Drug Basic Information

Table 100. Moderna Therapeutics Oligonucleotide Therapy-based Drug Product Overview

Table 101. Moderna Therapeutics Oligonucleotide Therapy-based Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 102. Moderna Therapeutics Business Overview

Table 103. Moderna Therapeutics Recent Developments

Table 104. Jazz Pharmaceuticals Oligonucleotide Therapy-based Drug Basic Information

Table 105. Jazz Pharmaceuticals Oligonucleotide Therapy-based Drug Product Overview

Table 106. Jazz Pharmaceuticals Oligonucleotide Therapy-based Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 107. Jazz Pharmaceuticals Business Overview

Table 108. Jazz Pharmaceuticals Recent Developments

Table 109. CureVac Oligonucleotide Therapy-based Drug Basic Information

Table 110. CureVac Oligonucleotide Therapy-based Drug Product Overview

Table 111. CureVac Oligonucleotide Therapy-based Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 112. CureVac Business Overview

Table 113. CureVac Recent Developments

Table 114. Regulus Therapeutics Oligonucleotide Therapy-based Drug Basic Information

Table 115. Regulus Therapeutics Oligonucleotide Therapy-based Drug Product Overview

Table 116. Regulus Therapeutics Oligonucleotide Therapy-based Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 117. Regulus Therapeutics Business Overview

Table 118. Regulus Therapeutics Recent Developments

Table 119. ProQR Oligonucleotide Therapy-based Drug Basic Information

Table 120. ProQR Oligonucleotide Therapy-based Drug Product Overview

Table 121. ProQR Oligonucleotide Therapy-based Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 122. ProQR Business Overview

Table 123. ProQR Recent Developments

Table 124. Secarna Oligonucleotide Therapy-based Drug Basic Information

Table 125. Secarna Oligonucleotide Therapy-based Drug Product Overview

Table 126. Secarna Oligonucleotide Therapy-based Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 127. Secarna Business Overview

Table 128. Secarna Recent Developments

Table 129. MiNA Therapeutics Oligonucleotide Therapy-based Drug Basic Information

Table 130. MiNA Therapeutics Oligonucleotide Therapy-based Drug Product Overview

Table 131. MiNA Therapeutics Oligonucleotide Therapy-based Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 132. MiNA Therapeutics Business Overview

Table 133. MiNA Therapeutics Recent Developments

Table 134. Sylentis Oligonucleotide Therapy-based Drug Basic Information

- Table 135. Sylentis Oligonucleotide Therapy-based Drug Product Overview
- Table 136. Sylentis Oligonucleotide Therapy-based Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
- Table 137. Sylentis Business Overview
- Table 138. Sylentis Recent Developments
- Table 139. Arrowhead Oligonucleotide Therapy-based Drug Basic Information
- Table 140. Arrowhead Oligonucleotide Therapy-based Drug Product Overview
- Table 141. Arrowhead Oligonucleotide Therapy-based Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
- Table 142. Arrowhead Business Overview
- Table 143. Arrowhead Recent Developments
- Table 144. Silence Therapeutics Oligonucleotide Therapy-based Drug Basic Information
- Table 145. Silence Therapeutics Oligonucleotide Therapy-based Drug Product Overview
- Table 146. Silence Therapeutics Oligonucleotide Therapy-based Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
- Table 147. Silence Therapeutics Business Overview
- Table 148. Silence Therapeutics Recent Developments
- Table 149. Dicerna Oligonucleotide Therapy-based Drug Basic Information
- Table 150. Dicerna Oligonucleotide Therapy-based Drug Product Overview
- Table 151. Dicerna Oligonucleotide Therapy-based Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
- Table 152. Dicerna Business Overview
- Table 153. Dicerna Recent Developments
- Table 154. Global Oligonucleotide Therapy-based Drug Sales Forecast by Region (2025-2032) & (K MT)
- Table 155. Global Oligonucleotide Therapy-based Drug Market Size Forecast by Region (2025-2032) & (M USD)
- Table 156. North America Oligonucleotide Therapy-based Drug Sales Forecast by Country (2025-2032) & (K MT)
- Table 157. North America Oligonucleotide Therapy-based Drug Market Size Forecast by Country (2025-2032) & (M USD)
- Table 158. Europe Oligonucleotide Therapy-based Drug Sales Forecast by Country (2025-2032) & (K MT)
- Table 159. Europe Oligonucleotide Therapy-based Drug Market Size Forecast by Country (2025-2032) & (M USD)
- Table 160. Asia Pacific Oligonucleotide Therapy-based Drug Sales Forecast by Region (2025-2032) & (K MT)
- Table 161. Asia Pacific Oligonucleotide Therapy-based Drug Market Size Forecast by

Region (2025-2032) & (M USD)

Table 162. South America Oligonucleotide Therapy-based Drug Sales Forecast by Country (2025-2032) & (K MT)

Table 163. South America Oligonucleotide Therapy-based Drug Market Size Forecast by Country (2025-2032) & (M USD)

Table 164. Middle East and Africa Oligonucleotide Therapy-based Drug Consumption Forecast by Country (2025-2032) & (Units)

Table 165. Middle East and Africa Oligonucleotide Therapy-based Drug Market Size Forecast by Country (2025-2032) & (M USD)

Table 166. Global Oligonucleotide Therapy-based Drug Sales Forecast by Type (2025-2032) & (K MT)

Table 167. Global Oligonucleotide Therapy-based Drug Market Size Forecast by Type (2025-2032) & (M USD)

Table 168. Global Oligonucleotide Therapy-based Drug Price Forecast by Type (2025-2032) & (USD/MT)

Table 169. Global Oligonucleotide Therapy-based Drug Sales (K MT) Forecast by Application (2025-2032)

Table 170. Global Oligonucleotide Therapy-based Drug Market Size Forecast by Application (2025-2032) & (M USD)

## List Of Figures

### LIST OF FIGURES

- Figure 1. Product Picture of Oligonucleotide Therapy-based Drug
- Figure 2. Data Triangulation
- Figure 3. Key Caveats
- Figure 4. Global Oligonucleotide Therapy-based Drug Market Size (M USD), 2019-2032
- Figure 5. Global Oligonucleotide Therapy-based Drug Market Size (M USD) (2019-2032)
- Figure 6. Global Oligonucleotide Therapy-based Drug Sales (K MT) & (2019-2032)
- Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
- Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
- Figure 9. Evaluation Matrix of Regional Market Development Potential
- Figure 10. Oligonucleotide Therapy-based Drug Market Size by Country (M USD)
- Figure 11. Oligonucleotide Therapy-based Drug Sales Share by Manufacturers in 2023
- Figure 12. Global Oligonucleotide Therapy-based Drug Revenue Share by Manufacturers in 2023
- Figure 13. Oligonucleotide Therapy-based Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
- Figure 14. Global Market Oligonucleotide Therapy-based Drug Average Price (USD/MT) of Key Manufacturers in 2023
- Figure 15. The Global 5 and 10 Largest Players: Market Share by Oligonucleotide Therapy-based Drug Revenue in 2023
- Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
- Figure 17. Global Oligonucleotide Therapy-based Drug Market Share by Type
- Figure 18. Sales Market Share of Oligonucleotide Therapy-based Drug by Type (2019-2024)
- Figure 19. Sales Market Share of Oligonucleotide Therapy-based Drug by Type in 2023
- Figure 20. Market Size Share of Oligonucleotide Therapy-based Drug by Type (2019-2024)
- Figure 21. Market Size Market Share of Oligonucleotide Therapy-based Drug by Type in 2023
- Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
- Figure 23. Global Oligonucleotide Therapy-based Drug Market Share by Application
- Figure 24. Global Oligonucleotide Therapy-based Drug Sales Market Share by Application (2019-2024)
- Figure 25. Global Oligonucleotide Therapy-based Drug Sales Market Share by Application in 2023

Figure 26. Global Oligonucleotide Therapy-based Drug Market Share by Application (2019-2024)

Figure 27. Global Oligonucleotide Therapy-based Drug Market Share by Application in 2023

Figure 28. Global Oligonucleotide Therapy-based Drug Sales Growth Rate by Application (2019-2024)

Figure 29. Global Oligonucleotide Therapy-based Drug Sales Market Share by Region (2019-2024)

Figure 30. North America Oligonucleotide Therapy-based Drug Sales and Growth Rate (2019-2024) & (K MT)

Figure 31. North America Oligonucleotide Therapy-based Drug Sales Market Share by Country in 2023

Figure 32. U.S. Oligonucleotide Therapy-based Drug Sales and Growth Rate (2019-2024) & (K MT)

Figure 33. Canada Oligonucleotide Therapy-based Drug Sales (K MT) and Growth Rate (2019-2024)

Figure 34. Mexico Oligonucleotide Therapy-based Drug Sales (Units) and Growth Rate (2019-2024)

Figure 35. Europe Oligonucleotide Therapy-based Drug Sales and Growth Rate (2019-2024) & (K MT)

Figure 36. Europe Oligonucleotide Therapy-based Drug Sales Market Share by Country in 2023

Figure 37. Germany Oligonucleotide Therapy-based Drug Sales and Growth Rate (2019-2024) & (K MT)

Figure 38. France Oligonucleotide Therapy-based Drug Sales and Growth Rate (2019-2024) & (K MT)

Figure 39. U.K. Oligonucleotide Therapy-based Drug Sales and Growth Rate (2019-2024) & (K MT)

Figure 40. Italy Oligonucleotide Therapy-based Drug Sales and Growth Rate (2019-2024) & (K MT)

Figure 41. Russia Oligonucleotide Therapy-based Drug Sales and Growth Rate (2019-2024) & (K MT)

Figure 42. Asia Pacific Oligonucleotide Therapy-based Drug Sales and Growth Rate (K MT)

Figure 43. Asia Pacific Oligonucleotide Therapy-based Drug Sales Market Share by Region in 2023

Figure 44. China Oligonucleotide Therapy-based Drug Sales and Growth Rate (2019-2024) & (K MT)

Figure 45. Japan Oligonucleotide Therapy-based Drug Sales and Growth Rate

(2019-2024) & (K MT)

Figure 46. South Korea Oligonucleotide Therapy-based Drug Sales and Growth Rate (2019-2024) & (K MT)

Figure 47. India Oligonucleotide Therapy-based Drug Sales and Growth Rate (2019-2024) & (K MT)

Figure 48. Southeast Asia Oligonucleotide Therapy-based Drug Sales and Growth Rate (2019-2024) & (K MT)

Figure 49. South America Oligonucleotide Therapy-based Drug Sales and Growth Rate (K MT)

Figure 50. South America Oligonucleotide Therapy-based Drug Sales Market Share by Country in 2023

Figure 51. Brazil Oligonucleotide Therapy-based Drug Sales and Growth Rate (2019-2024) & (K MT)

Figure 52. Argentina Oligonucleotide Therapy-based Drug Sales and Growth Rate (2019-2024) & (K MT)

Figure 53. Columbia Oligonucleotide Therapy-based Drug Sales and Growth Rate (2019-2024) & (K MT)

Figure 54. Middle East and Africa Oligonucleotide Therapy-based Drug Sales and Growth Rate (K MT)

Figure 55. Middle East and Africa Oligonucleotide Therapy-based Drug Sales Market Share by Region in 2023

Figure 56. Saudi Arabia Oligonucleotide Therapy-based Drug Sales and Growth Rate (2019-2024) & (K MT)

Figure 57. UAE Oligonucleotide Therapy-based Drug Sales and Growth Rate (2019-2024) & (K MT)

Figure 58. Egypt Oligonucleotide Therapy-based Drug Sales and Growth Rate (2019-2024) & (K MT)

Figure 59. Nigeria Oligonucleotide Therapy-based Drug Sales and Growth Rate (2019-2024) & (K MT)

Figure 60. South Africa Oligonucleotide Therapy-based Drug Sales and Growth Rate (2019-2024) & (K MT)

Figure 61. Global Oligonucleotide Therapy-based Drug Production Market Share by Region (2019-2024)

Figure 62. North America Oligonucleotide Therapy-based Drug Production (K MT) Growth Rate (2019-2024)

Figure 63. Europe Oligonucleotide Therapy-based Drug Production (K MT) Growth Rate (2019-2024)

Figure 64. Japan Oligonucleotide Therapy-based Drug Production (K MT) Growth Rate (2019-2024)

Figure 65. China Oligonucleotide Therapy-based Drug Production (K MT) Growth Rate (2019-2024)

Figure 66. Global Oligonucleotide Therapy-based Drug Sales Forecast by Volume (2019-2032) & (K MT)

Figure 67. Global Oligonucleotide Therapy-based Drug Market Size Forecast by Value (2019-2032) & (M USD)

Figure 68. Global Oligonucleotide Therapy-based Drug Sales Market Share Forecast by Type (2025-2032)

Figure 69. Global Oligonucleotide Therapy-based Drug Market Share Forecast by Type (2025-2032)

Figure 70. Global Oligonucleotide Therapy-based Drug Sales Forecast by Application (2025-2032)

Figure 71. Global Oligonucleotide Therapy-based Drug Market Share Forecast by Application (2025-2032)

## I would like to order

Product name: Global Oligonucleotide Therapy-based Drug Market Research Report 2024, Forecast to 2032

Product link: <https://marketpublishers.com/r/GD652840ADA6EN.html>

Price: US\$ 3,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GD652840ADA6EN.html>